NASDAQ:GRTX Galera Therapeutics (GRTX) Stock Forecast, Price & News $3.12 +0.05 (+1.63%) (As of 12:26 PM ET) Add Compare Share Share Today's Range$3.01▼$3.1350-Day Range$2.13▼$3.3452-Week Range$1.12▼$3.50Volume129,428 shsAverage Volume611,208 shsMarket Capitalization$133.88 millionP/E RatioN/ADividend YieldN/APrice Target$7.75 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Galera Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside152.4% Upside$7.75 Price TargetShort InterestHealthy2.43% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$212,350 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.66) to ($1.55) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.12 out of 5 starsMedical Sector505th out of 1,006 stocksPharmaceutical Preparations Industry243rd out of 492 stocks 3.5 Analyst's Opinion Consensus RatingGalera Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.75, Galera Therapeutics has a forecasted upside of 152.4% from its current price of $3.07.Amount of Analyst CoverageGalera Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.43% of the float of Galera Therapeutics has been sold short.Short Interest Ratio / Days to CoverGalera Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldGalera Therapeutics does not currently pay a dividend.Dividend GrowthGalera Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GRTX. Previous Next 2.7 News and Social Media Coverage News SentimentGalera Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.Search InterestOnly 6 people have searched for GRTX on MarketBeat in the last 30 days. This is a decrease of -77% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Galera Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Galera Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $212,350.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 8.60% of the stock of Galera Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 36.45% of the stock of Galera Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Galera Therapeutics are expected to grow in the coming year, from ($1.66) to ($1.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Galera Therapeutics is -1.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Galera Therapeutics is -1.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Galera Therapeutics (NASDAQ:GRTX) StockGalera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.Read More Receive GRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address GRTX Stock News HeadlinesMay 18, 2023 | finance.yahoo.comGalera Announces FDA Orphan Drug Designation Granted to Rucosopasem for Pancreatic CancerMay 18, 2023 | finance.yahoo.comGalera Therapeutics, Inc.'s (NASDAQ:GRTX) largest shareholders are retail investors with 45% ownership, institutions own 34%June 1, 2023 | Edge On The Street (Ad)AI is Unstoppable. Now Is The Time!AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.May 11, 2023 | finanznachrichten.deGalera Therapeutics: Galera Reports First Quarter 2023 Financial Results and Recent Corporate UpdatesMay 11, 2023 | finance.yahoo.comGalera Reports First Quarter 2023 Financial Results and Recent Corporate UpdatesMay 4, 2023 | finance.yahoo.comGalera Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2023 | finance.yahoo.comGalera Expands Commercial Leadership TeamApril 26, 2023 | finance.yahoo.comGalera to Present One-Year Reductions in Cisplatin-Related Chronic Kidney Disease Data from ROMAN Trial at 2023 American Society of Clinical Oncology (ASCO) Annual MeetingJune 1, 2023 | Edge On The Street (Ad)AI is Unstoppable. Now Is The Time!AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.March 26, 2023 | americanbankingnews.comGalera Therapeutics, Inc. (NASDAQ:GRTX) to Post Q1 2023 Earnings of ($0.31) Per Share, HC Wainwright ForecastsMarch 25, 2023 | americanbankingnews.comHC Wainwright Comments on Galera Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:GRTX)March 25, 2023 | americanbankingnews.comGalera Therapeutics, Inc. Forecasted to Earn FY2024 Earnings of ($0.66) Per Share (NASDAQ:GRTX)March 24, 2023 | americanbankingnews.comGalera Therapeutics (NASDAQ:GRTX) Price Target Cut to $6.00March 23, 2023 | benzinga.comGalera Therapeutics Stock (NASDAQ:GRTX), Analyst Ratings, Price Targets, PredictionsMarch 23, 2023 | americanbankingnews.comHC Wainwright Trims Galera Therapeutics (NASDAQ:GRTX) Target Price to $6.00March 22, 2023 | markets.businessinsider.comAnalyst Ratings for Galera TherapeuticsMarch 22, 2023 | markets.businessinsider.comWhere Galera Therapeutics Stands With AnalystsMarch 22, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Galera Therapeutics (GRTX)March 22, 2023 | americanbankingnews.comInsider Buying: Galera Therapeutics, Inc. (NASDAQ:GRTX) Insider Acquires 11,000 Shares of StockMarch 10, 2023 | finance.yahoo.comGalera Announces Presentation of Supplemental Analysis of Phase 3 ROMAN Trial at European Congress on Head and Neck OncologyMarch 8, 2023 | finance.yahoo.comThese 2 ‘Strong Buy’ Penny Stocks Are Poised for a Massive Rally, Say AnalystsMarch 8, 2023 | finanznachrichten.deGalera Therapeutics: Galera Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate UpdatesMarch 8, 2023 | finance.yahoo.comGalera Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate UpdatesMarch 2, 2023 | benzinga.comGalera Therapeutics Chief Financial Officer Awarded $331K Worth of Stock OptionsMarch 1, 2023 | benzinga.comGalera Therapeutics Chief Operating Officer Awarded $241K Worth of Stock OptionsMarch 1, 2023 | benzinga.comPresident and CEO at Galera Therapeutics Acquires Company Stock Options Worth 440,000 SharesMarch 1, 2023 | benzinga.comGalera Therapeutics Chief Commercial Officer Awarded $241K Worth of Stock OptionsSee More Headlines GRTX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GRTX Company Calendar Last Earnings3/08/2023Today6/01/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GRTX CUSIPN/A CIK1563577 Webwww.galeratx.com Phone610-725-1500FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Forecast$7.75 High Stock Price Forecast$12.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+152.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,220,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-119.68% Debt Debt-to-Equity RatioN/A Current Ratio4.09 Quick Ratio4.09 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($2.28) per share Price / Book-1.35Miscellaneous Outstanding Shares42,910,000Free Float39,217,000Market Cap$131.73 million OptionableNot Optionable Beta1.82 Key ExecutivesDr. J. Mel Sorensen M.D. (Age 65)CEO, Pres & Director Comp: $820.77kMr. Christopher Degnan (Age 42)Chief Financial Officer Comp: $529.35kMr. Mark J. Bachleda M.B.A. (Age 47)Pharm.D., Chief Commercial Officer Comp: $476.5kDr. Robert A. Beardsley M.B.A. (Age 60)Ph.D., Co-Founder & COO Dr. Dennis P. Riley Ph.D.Chief Scientific Officer, EmeritusMs. Jennifer Evans Stacey Esq. (Age 57)Chief Legal & Compliance Officer and Sec. Dr. Jon T. Holmlund M.D. (Age 65)Exec. Officer Ms. Andie CollierSr. VP of Regulatory AffairsMs. Judy SchnyderSr. VP of Clinical Operations & Data ManagementDr. Eugene P. Kennedy F.A.C.S. (Age 53)FACS, M.D., Chief Medical Officer More ExecutivesKey CompetitorsIncannex HealthcareNASDAQ:IXHLESSA PharmaNASDAQ:EPIXCelularityNASDAQ:CELUAffimedNASDAQ:AFMDOrganigramNASDAQ:OGIView All CompetitorsInsiders & InstitutionsGeode Capital Management LLCBought 21,316 shares on 5/16/2023Ownership: 0.457%State Street CorpBought 54,000 shares on 5/16/2023Ownership: 0.193%Jane Street Group LLCBought 9,450 shares on 5/16/2023Ownership: 0.046%Susquehanna International Group LLPBought 11,200 shares on 5/16/2023Ownership: 0.000%Two Sigma Investments LPBought 21,791 shares on 5/15/2023Ownership: 0.051%View All Insider TransactionsView All Institutional Transactions GRTX Stock - Frequently Asked Questions Should I buy or sell Galera Therapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Galera Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GRTX shares. View GRTX analyst ratings or view top-rated stocks. What is Galera Therapeutics' stock price forecast for 2023? 3 Wall Street research analysts have issued 12 month target prices for Galera Therapeutics' stock. Their GRTX share price forecasts range from $6.00 to $12.00. On average, they expect the company's share price to reach $7.75 in the next year. This suggests a possible upside of 152.4% from the stock's current price. View analysts price targets for GRTX or view top-rated stocks among Wall Street analysts. How have GRTX shares performed in 2023? Galera Therapeutics' stock was trading at $1.49 at the beginning of 2023. Since then, GRTX stock has increased by 106.0% and is now trading at $3.07. View the best growth stocks for 2023 here. When is Galera Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our GRTX earnings forecast. How were Galera Therapeutics' earnings last quarter? Galera Therapeutics, Inc. (NASDAQ:GRTX) released its quarterly earnings results on Wednesday, March, 8th. The company reported ($0.58) EPS for the quarter, missing analysts' consensus estimates of ($0.50) by $0.08. What other stocks do shareholders of Galera Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Galera Therapeutics investors own include Fulcrum Therapeutics (FULC), Ardelyx (ARDX), Chiasma (CHMA), Provention Bio (PRVB), Seelos Therapeutics (SEEL), Soligenix (SNGX), TG Therapeutics (TGTX) and VBI Vaccines (VBIV). When did Galera Therapeutics IPO? (GRTX) raised $75 million in an initial public offering on Thursday, November 7th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Citigroup and Credit Suisse served as the underwriters for the IPO and BTIG was co-manager. What is Galera Therapeutics' stock symbol? Galera Therapeutics trades on the NASDAQ under the ticker symbol "GRTX." Who are Galera Therapeutics' major shareholders? Galera Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Sectoral Asset Management Inc. (4.89%), BlackRock Inc. (0.74%), Renaissance Technologies LLC (0.47%), Geode Capital Management LLC (0.46%), Schonfeld Strategic Advisors LLC (0.32%) and State Street Corp (0.19%). Insiders that own company stock include Bioventures Ltd Novartis, Chris Degnan, Holdings A/S Novo, Joel F Sussman, Jon T Holmlund, Linda West, Mark Bachleda and Mel Sorensen. View institutional ownership trends. How do I buy shares of Galera Therapeutics? Shares of GRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Galera Therapeutics' stock price today? One share of GRTX stock can currently be purchased for approximately $3.07. How much money does Galera Therapeutics make? Galera Therapeutics (NASDAQ:GRTX) has a market capitalization of $131.73 million. The company earns $-62,220,000.00 in net income (profit) each year or ($2.22) on an earnings per share basis. How can I contact Galera Therapeutics? Galera Therapeutics' mailing address is 2 WEST LIBERTY BOULEVARD SUITE 100, MALVERN PA, 19355. The official website for the company is www.galeratx.com. The company can be reached via phone at 610-725-1500 or via email at cdegnan@galeratx.com. This page (NASDAQ:GRTX) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.